February 5, 2026
IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
Revenue of $4,364 million for the fourth quarter, $16,310 million for the full year GAAP Net Income of $514 million…
Pharmaceuticals, Biotechnology and Life Sciences
Revenue of $4,364 million for the fourth quarter, $16,310 million for the full year GAAP Net Income of $514 million…
Latest investment marks key milestone in the company’s global growth strategy, supporting clients across an increasingly complex healthcare landscape LONDON–(BUSINESS…
Validated, tissue-specific library enables customisable and controllable liver-targeted gene expression with high specificity and minimal off-target activity in muscle tissue…
MINATO-KU, TOKYO, Japan & KOBE, Japan–(BUSINESS WIRE)–#IVD–Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated…
SAN DIEGO–(BUSINESS WIRE)–Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the…
– Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology – HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals…
Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of…
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s…
The need for more effective protection against influenza continues to grow, as the virus consistently causes significant illness and mortality…
Study highlights GLP-1 companion effects, underscoring capability of Brightseed’s AI platform to identify and launch clinically-validated, natural health innovations SOUTH…